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Abstract  
Naturally occurring pyridone alkaloids as well as synthetic derivatives were previously 
shown to induce neurite outgrowth. However, the molecular basis for this biological effect 
remains poorly understood. In this work, we have prepared new pyridones, and tested the 
effect of thirteen 4-hydroxy-2-pyridone derivatives on the components of the 
endocannabinoid system. Investigation of binding affinities towards CB1 and CB2 
receptors led to the identification of a compound binding selectively to CB1 (12). 
Compound 12 and a closely related derivative (11) also inhibited anandamide (AEA) 
hydrolysis by fatty acid amide hydrolase. Interestingly, none of the compounds tested 
showed any effect on 2-AG hydrolysis by monoacylglycerol lipase at 10 µM. Assessment 
of AEA uptake did, however, lead to the identification of four inhibitors with IC50 values in 
the submicromolar range and high selectivity over the other components of the 
endocannabinoid system. 
1. Introduction 
Hydroxy-2-pyridones constitute a compelling class of secondary metabolites,[1] which 
have been suggested to act as chemical mediators in interactions between 
entomopathogenic fungi and their insect hosts. Over the past years, a number of biological 
activities have been reported for these compounds, mostly focusing on their in vitro 
properties, such as cytotoxicity.[2] For example, ricinine, a 2-pyridone alkaloid first isolated 
from castor oil plants in the 19th century,[3] has long been known as an insecticide[4] and 
lately been reported to have stimulatory effects on the central nervous system.[5] 
Pronounced antifungal activity has been observed with the structurally more complex 
compounds ilicicolin H,[2d, 6] apiosporamide,[7] and YM-215343.[2e] However, the molecular 
targets of 4-hydroxy-2-pyridones have generally remained elusive.[8] A recent study by the 
group of Waldmann, however, demonstrated an inhibitory effect on kinase activity, and a 
crystal structure of 3-acyl-4-hydroxy-2-pyridone complexed with wild-type mitogen-
activated protein kinase 4 (MAP4K4) with the inhibitor residing in the ATP binding site 
supports this hypothesis.[9] 
There have been numerous efforts directed towards the total synthesis of 4-hydroxy-2-
pyridones, as it is difficult to obtain these alkaloids in pure form from natural sources.[10] 
The work of one of our groups has focused on a family of 3-acyl-4-hydroxy-2-pyridone 
alkaloids isolated from entomopathogenic fungi (Table 1).[2b, 11] Chemical synthesis 
yielded the congeners pretenellin B, prebassianin B, farinosone A, militarinone D and 
another homologue of the militarinone family (HJJ-510). All of these substances show 
neuritogenic activity in the PC12 cell assay.[12] Based on these phenotypic observations, 
we became interested in the potential mechanism of action of these compounds. 
 
Table 1: Family of pyridone alkaloids from entomopathogenic fungi. 
 
 
R = H, n = 1 
R = OH, n = 1 
R = H, n = 2 
R = OH, n = 2 
R = H, n = 3 
R = OH, n = 3 
pretenellin B 
tenellin 
prebassianin B 
bassianin 
farinosone A 
farinosone B 
 
 
R = H, n = 1 
R = OH, n = 1 
R = H, n = 2 
R = OH, n = 2 
unknown (HJJ-510) 
unknown 
militarinone D 
unknown 
 
 
X = CH3, n = 1 
X = H, n = 2 
pyridovericin 
torrubiellone C 
 
The structurally related compound farinosone C triggers neurite outgrowth, and we have 
shown that structurally simplified analogues retain this activity.[13] In order to investigate 
the underlying biochemical pathways responsible for neurite outgrowth, these substances 
were tested for their ability to bind to cannabinoid receptors (CB1 and CB2). It had been 
previously reported that CB1 receptor activation promotes neuritogenesis in Neuro-2A 
cells via a complex signalling pathway[14] and to restore neuritogenic activity in 
hyperglycemic PC12 cells.[15] One of the farinosone C analogues (BSL-34; Scheme 1) 
very effectively inhibits anandamide (AEA) uptake – most likely by interacting with the 
putative endocannabinoid membrane transporter, which is supposed to regulate the 
bidirectional shuttle of endocannabinoids across the plasma membrane or via interaction 
with cytoplasmic shuttle proteins.[16] 
 
Scheme 1: Neuritogenic compounds farinosone C and BSL-34. 
 
 
Based on these observations, we reasoned that AEA uptake inhibition might be the cause 
for the neuritogenic effects exhibited by BSL-34 because such inhibition would lead to an 
increase in the extracellular concentrations of AEA, which can in turn activate cannabinoid 
receptors. In addition, increasing levels of AEA might also affect TRPV1 activity, which 
plays a role in neuronal differentiation of SH-SY5Y human neuroblastoma cells.[17] 
Therefore, we investigated whether the neuritogenic effects of the pyridone alkaloids are 
related to activation of CB1 and CB2 and/or indirect modulation of AEA levels by inhibition 
of the degrading enzymes and/or specifically AEA uptake. All compounds tested – eight 
natural products, two truncated ester derivatives and three derivatives with ketone side 
chains of various length – are shown in Table 2. 
 
Table 2. Chemical structure of the pyridone alkaloids tested on the different components 
of the ECS and known inhibitors for positive controls. 
 
entry name structure 
1 farinosone A 
 
2 militarinone D 
 
3 torrubiellone C 
 
4 HJJ-510 
 
5 prebassianin B 
 
6 SF-182 
 
7 pretenellin B 
 
8 pyridovericin 
 
9 NM33 
 
10 NM34/36 
 
11 NM56 
 
12 NM57 
 
13 NM58 
 
14 CP55940 
 
15 UCM707[18] 
 
16 JZL184[19] 
 
17 WWL70[20] 
 
18 THL[20] 
 
19 URB597[18, 21] 
 
20 DuP697[22] 
 
21 OMDM-2[23] 
 
22 WIN55,212-2[24] 
 
 
2. Chemistry 
The natural products tested in this study for their activity towards components of the 
endocannabinoid system were obtained by total synthesis as reported in literature.[10i, 12, 
25] As we aimed to produce 4-hydroxy-2-pyridone derivatives with diverse side chains at 
position C-3, we first envisioned a late-stage transacylation of the methyl ester analogue 
(27) of the known ethyl ester intermediate from the total synthesis of natural pyridone 
alkaloids.[12] We thus prepared methyl (Z)-2-cyano-3-methoxybut-2-enoate by conden-
sation of methyl cyanoacetate (22) with trimethylorthoacetate according to a procedure 
first reported by Arndt in 1936 with concomitant distillation of methanol.[26] Upon cooling, 
the product solidified. It was re-crystallized from an aqueous methanol solution (62 % 
yield) and used without further purification in the subsequent condensation with N,N-
dimethylformamide dimethyl acetal to give the bright yellow push-pull substituted olefin 23 
with 74 % yield. Heating this enamine in acetic acid triggers nucleophilic attack of the 
amino group at the cyano group, finally leading to formation of the pyridine ring, as 
reported by the group of Prager.[27] However, due to the harsh reaction conditions this 
procedure is prone to side product formation and the isolated yield of the desired product 
was only 40 %. Subsequently, the pyridone ring was site-selectively brominated in 5-
position with an excellent yield of 96 % to give methyl 5-bromo-4-methoxy-2-oxo-1,2-
dihydropyridine-3-carboxylate 24. As in the total synthesis of pyridone alkaloid natural 
products,[12] the pyridone ring was protected by reaction with 2-(trimethylsilyl)ethoxy-
methyl chloride giving the N-SEM (25a) and the O-SEM product (25b) in a ratio of 4:3. 
Both derivatives undergo facile Suzuki coupling with {4-[(4-methoxybenzyl)oxy]phenyl}-
boronic acid, but in this study the N-SEM isomer was further utilized. With the PMB-
protected 4-hydroxy aryl group installed (26), we now tested the attempted 
transesterification under mild conditions as reported by Seebach and co-workers.[28] Using 
molecular sieves as a scavenger for methanol, we were able to obtain the pentenyl (27) 
and decanyl ester (28) in moderate yields of 28 % and 22 % with the desired concomitant 
deprotection of the hydroxyl group on position C-4 of the heterocycle, which is much more 
critical to carry out at a later stage of the synthesis. Deprotection of the pyridone ring and 
the phenol with TBAF and TFA, respectively, gave the desired products 9 and 10.  
 
Scheme 2: The transesterification route to pyridine alkaloid derivatives. 
 
Due to the limitations of this route regarding general applicability and yield, we prepared 
derivatives with ketone side chains of different length following synthetic procedures 
established by Baldwin and Waldmann.[9, 10h] One of the key advantages of this route is 
the possibility to start from commercially available 2,4-dihydroxy pyridine (29) without 
having to form the heterocyclic ring. Following procedures reported by Baldwin et al.,[10h] 
a double bromination led to 3,5-dibromopyridine-2,4-diol in 71 % yield after recrystalli-
zation from ethanol/water. Protection of the free hydroxyl groups with methyl iodide in the 
presence of silver carbonate proceeded sluggishly to give the desired 3,5-dibromo-2,4-
dimethoxypyridine (30) in 74 % yield after stirring the reaction mixture for five days at room 
temperature. The step conferring structural diversity is the subsequent regioselective 
lithiation and alkylation. With octanal, dodecanal and octadecanal this reaction proceeded 
with good to excellent yields to give the racemic mixtures of alcohols 31–33. The protected 
4-hydroxy aryl group was installed by Suzuki coupling with [(tert-butyldimethylsilyl)-
oxy]phenyl boronic acid following procedures of Waldmann and coworkers.[9] Subsequent 
Dess-Martin oxidation of 34–36 (82–94 % yield) was followed by deprotection of both the 
4-hydroxy group and the phenol to give the desired pyridone compounds 11–13 in good 
yield. Although the diversifying key step is carried out early on, this strategy proved to be 
much more effective as it comprises only six synthetic steps, most of them with high to 
excellent yields. 
 
 
Scheme 3: Alkylation-Suzuki route for the preparation of pyridone alkaloid derivatives. 
 
We were thus able to assess the biological activity of eight natural products, two truncated 
ester derivatives and three derivatives with ketone side chains of various length (Table 2). 
3. Results and discussion 
Thirteen 4-hydroxy-2-pyridone compounds were tested for their activity on the different 
components of the endocannabinoid system (ECS). The molecular structure of the 
compounds is given in Table 2. Among them are natural products such as farinosone A, 
militarinone D, torrubiellone C, prebassianin B and pyridovericin, which have been 
produced by total synthesis.[10h-j, 12, 25] Entries 4 and 6 represent compounds that are 
structurally very similar, but have not been isolated from natural sources. As the side chain 
of 4-hydroxy-2-pyridones was shown to hardly have any influence on their neuritogenic 
activity in PC12 cell assays,[29] truncated structurally simplified derivatives with an ester 
and a ketone side-chain of different lengths were included as well.  
 
First, we investigated the binding properties to CB1 and CB2 receptors.[30] As reported in 
Fig. 1A, HJJ-510 (4) and pretenellin B (7) showed a very weak binding to CB1 defined by 
approximately 40 % displacement of [3H]CP55,940 at a concentration of 1 µM. Compound 
12 reached 50 % displacement of the radioligand and was assessed in a full 
concentration-dependent curve showing a Ki value of 1.0 µM (Fig. 1B). In contrast, the 
other structurally simplified pyridones did not show any significant binding to CB1 and CB2 
receptors (< 20 %) at a concentration of 1 µM (Fig 1A). Compound 12 did not bind to CB2 
receptors, thus showing a selective interaction with CB1 receptors. 
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Fig. 1. A: CB1 and CB2 receptors binding properties of pyridone alkaloids tested at the 
screening concentration of 1 µM. B: Concentration-dependent binding curve for 
compound 12 to CB1 receptors. 
 
We then investigated the effects of these compounds on 2-OG hydrolysis by monoacyl-
glycerol lipase (MAGL), a,b-hydrolase domain-6 (ABHD6) and -12 (ABHD12), as well as 
AEA hydrolysis by fatty acid amide hydrolase (FAAH). As shown in Fig. 2A, none of the 
tested compounds showed significant inhibition of MAGL activity at the concentration of 
10 µM. Similarly, our compound library did not inhibit ABHD6 and ABDH12, as compared 
to the positive control compounds WWL70 (17) and THL (18) used for the ABHD6 and 
ABHD12 assay, respectively (data not shown).[20] In contrast, militarinone D (2), 10 and 
12 inhibited FAAH activity by 40–50 % at 10 µM, while compound 11 inhibited AEA 
hydrolysis by 80 % compared to vehicle. In further concentration-dependent experiments, 
11 showed an IC50 value of 4.6 µM (Fig. 2B). Interestingly, this compound did not show 
any significant inhibition of MAGL, thus indicating a selectivity towards FAAH inhibition. 
 
Fig. 2. A: FAAH and MAGL activity upon treatment with the seven natural pyridone 
alkaloids and five simplified analogs tested at the screening concentration of 10 µM. 
URB597 (19) (1 µM)[21] and JZL184 (16)[19] (1 µM) were used as positive control for FAAH 
and MAGL inhibition, respectively. B: Concentration-dependent inhibition of FAAH activity 
induced by 11 in U937 cell homogenate. 
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Alternatively, AEA and 2-AG can undergo oxidative metabolism mediated by COX-2 
activity.[31] This degradation pathway generates prostaglandin-ethanolamines and 
prostaglandin-glycerol esters, which were shown to possess bioactivity unrelated to the 
interaction with cannabinoid receptors and the classic prostaglandin receptors. In the last 
years, it has been observed that several compounds can act as specific inhibitors by 
blocking the COX-2-mediated oxygenation of AEA and 2-AG without affecting arachidonic 
acid oxidation.[32] Here, we tested the pyridone alkaloids for the inhibition of COX-2-
mediated oxidation of the classic substrate arachidonic acid or the endocannabinoid 2-
AG. As shown in Fig. 3, some of the compounds showed partial inhibition of COX-2 
(ranging from 20 % to 50 %) at a screening concentration of 10 µM, which was not 
selective for either of the substrates.  
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Fig. 3. COX-2 activity upon treatment with the natural pyridone alkaloids and derivatives 
at a screening concentration of 10 µM using either arachidonic acid or 2-AG as substrate. 
DuP697 (1 µM)[22] (20) was used as a positive control. 
 
Finally, all compounds were screened on AEA uptake using U937 cells as previously 
described. At a concentration of 10 µM, farinosone A (1) induced the most potent inhibition 
of AEA uptake (Fig. 4A) and in further concentration-dependent experiments, it showed 
an IC50 value of 1.2 µM (Fig. 4B), being in range with the potency reported for the positive 
controls UCM707[18] and OMDM-2.[23, 33] Militarinone D (2), SF-182 (6) and pretenellin B 
(7) only partially inhibited AEA uptake at 10 µM, while torrubiellone C (3), HJJ-510 (4), 
prebassianin B (5) and pyridovericin (8) were inactive (Fig. 4A). This data indicates that, 
in comparison to farinosone A (1), shorter side chains in combination with a lower degree 
of unsaturation (4 and 5) and in the presence of a hydroxyl group (3 and 8) lead to impaired 
binding capacity.  
The synthetic analogs of the natural pyridone alkaloids (9–13) were also tested under the 
same conditions. At a concentration of 10 µM, 10, 11and 12 induced maximal inhibition of 
AEA uptake in the same range as the positive controls (Fig. 4A). In further concentration-
dependent experiments, these compounds showed IC50 values in the submicromolar 
range (0.67–0.78 µM) (Fig 4B). In contrast, compounds 9 and 13 were inactive (Fig. 4A). 
This indicates that fully saturated unbranched side chains in the range of C8–C12 (10–12) 
represent the optimal length for inhibition of AEA uptake , as compared to longer (C20, 13) 
and shorter (C4, 9) chains. When comparing natural pyridone alkaloids with their synthetic 
analogs, the data indicates that branched side chains (1–8) are less favourable for AEA 
uptake inhibition as compared to linear alkyl side chains (10–12). 
 
 
Fig. 4. A: Inhibition of AEA uptake into U937 cells induced by natural pyridone alkaloids 
and their analogs at a screening concentration of 10 µM. B: The most potent inhibitors 
were tested in concentration-dependent experiments. UCM707 (15)[18] and OMDM-2 
(21)[23] (both at 10 µM) were used as positive controls. Data in graph B have been 
normalized. 
 
AEA hydrolysis and uptake are coupled processes as the FAAH-dependent AEA 
concentration gradient needs to be maintained. This gradient is the driving force for AEA’s 
energy-independent uptake.[16b, 34] In cellular systems, FAAH inhibitors can indirectly 
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inhibit AEA uptake by affecting this concentration gradient,[34-35] and a correlation between 
IC50 values for FAAH and AEA uptake inhibition was reported.[36] Importantly, farinosone 
A (1) and the synthetic analogs 10–12 showed IC50 values >10 µM for FAAH. These 
compounds also showed IC50 values >10 µM for MAGL and COX-2. Thus, 1 and 10–12 
are selective inhibitors of AEA uptake (Table 3). Among them, only 12 showed weak 
binding to the CB1 receptor (Ki = 1.0 µM), while the other compounds did not significantly 
bind to CB1 or CB2 (0–30% binding at 1 µM).  
 
Table 3. Summary of the Ki and IC50 values of natural pyridone alkaloids 1 and their 
analogs 10-13 on the different components of the ECS. 
 Ki value (CB1 and CB2) or IC50 values (mean ± SD, µM) 
Compound CB1 CB2 FAAH MAGL 
AEA 
uptake 
COX-2 
1 >1 >1 >10 >10 1.2 ± 0.6 >10 
10 >1 >1 >10 >10 0.6 ± 0.4 >10 
11 >1 >1 >10 >10 0.7 ± 0.4 >10 
12 1.0 ± 0.5 >1 4.6 ± 0.7 >10 0.8 ± 0.3 >10 
13 >1 >1 >10 >10 >10 >10 
 
4. Conclusion 
In conclusion, we describe that the natural products 1, 2, 6 and 8 as well as synthetic 
pyridone alkaloids 10–12 act as AEA uptake inhibitors. Their IC50 values lie in the 
micromolar (1, 2, 6, 8) and in submicromolar (10–12) range and a selectivity >10 fold over 
the main components of the ECS, including FAAH. In agreement with other studies on 
different scaffolds, our results indicate that small modifications of the pyridone alkaloid 
side chain in terms of length, branching, degree of unsaturation and the presence of 
hydrophilic substituents can lead to a significant loss of potency for AEA uptake 
inhibition.[34-36]  
  
 5. Experimental section 
5.1 Chemistry 
The total syntheses of natural products 1–8 have been published by one of our groups 
and the substance samples used in this work have been produced by these 
procedures.[10i, 12, 25] Derivatives 9–13 are novel compounds that have not been reported 
elsewhere. Esters 9 and 10 are produced by transesterification of the respective methyl 
ester derivatives. The preparation of ketones 11–13 has been carried out in close analogy 
to previously reported synthetic work by the groups of Baldwin and Waldmann.[9, 10h] All 
synthetic procedures as well as analytical data of all intermediates can be found in the 
Supporting Information. Chemicals and solvents used for reactions were supplied by 
Sigma-Aldrich, Alfa Aesar, Fluka, Fluorochem, Maybridge, Acros, and Merck, and were 
used without further purification. Distilled technical grade solvents were used for column 
chromatography and work-up. Solvents were removed in vacuo on a rotary evaporator 
with 40 °C water bath temperature. Unless otherwise stated, reactions were carried out 
under argon atmosphere and reactions involving air-sensitive reagents were carried out 
using solvents degassed by freeze-pump-thaw cycling. Deuterated solvents used for NMR 
spectroscopy were supplied by Cambridge Isotope Laboratories. All reported yields are 
isolated yields, unless otherwise indicated. Flash chromatography was performed by dry-
pack method using silica gel with particles size between 0.040 and 0.063 mm as stationary 
phase according to the procedure developed by Mitra and coworkers.[37] Thin layer 
chromatography was performed on silica gel-coated glass plates (Merck 60 F254, 
thickness: 210–270 µm), spots were observed under UV light (l = 254 nm) and plates 
were stained with potassium permanganate solution. Preparative HPLC purifications were 
carried out on a Dionex Chromatography System (Interface Chromeleon, ASI 100 
automatic sample injector, PDA 100 (USB) PD detector, pump P680); flow rate: 20 mL 
min-1; column: Phenomenex Synergi Hydro-RP, 10 µm, 80 Å, 250 mm x 21.2 mm); 
solvents: A – H2O, B – MeCN. 
Method 1: from 80 % B to 100 % B over 2 minutes and maintaining 100 % B during 40 
minutes. Method 2: from 50 % B to 100 % B over 25 minutes and maintained 100 % B 
during 15 minutes. Reversed-phase LC-MS analyses were performed on a Shimadzu LC 
system with a Reprospher column (Dr. Maisch, 100 Å C18-Aqua, 5 µm, 125 mm x 2 mm) 
and an amaZon X Bruker mass spectrometer. The solvents used were demineralized 
water (milli-Q, 0.01 % formic acid, solvent A) and acetonitrile (HPLC grade, 0.01% formic 
acid, solvent B) at a flow rate of 0.5 mL min-1. The gradient applied was 0.0–2.0 minutes 
10 % B; 2.0–12.0 minutes 10 % B to 95 % B; 12.0–15.0 minutes 95 % B; 15.0–16.0 
minutes 95 % B to 10 % B; 16.0–18.0 minutes 10 % B. NMR experiments were performed 
on Bruker Avance III NMR spectrometers operating at 250 MHz, 400 MHz or 500 MHz 
proton frequency. Chemical shifts d are reported in ppm and were determined by referen-
ce to the residual 1H solvent peaks (chloroform: 7.26 ppm (1H) and 77.16 (13C); DMSO: 
2.50 ppm (1H) and 39.52 ppm (13C); methanol: 3.31 ppm (1H), 49.00 ppm(13C).[38] The 
assignment of signals in the 1H and 13C NMR spectra was achieved by interpretation of 
DEPT and two-dimensional NMR spectra (COSY, NOESY, HMBC and HSQC). 
Processing, analyses and interpretations of NMR spectra were performed with 
MestReNova (version: 10.0.1-14719). Infrared spectra were recorded using a Varian 800 
FT-IR ATR Spectrometer. The absorptions were reported in cm–1, both the intensity and 
profile of signals were described as weak, medium, strong or broad. ESI-HRMS spectra. 
Melting points (m.p.) were determined in open capillaries using a Büchi B-545 apparatus. 
Methyl (Z)-2-cyano-3-methoxybut-2-enoate.[26] In a one-necked 100 ml round-bottomed 
flask, methyl cyanoacetate (18.0 mL, 20.1 g, 0.203 mol, 1.0 equiv) and trimethyl 
orthoacetate (28.86 g, 0.240 mol, 1.2 equiv) were stirred at 110 °C and the methanol 
formed during this reaction was removed via a short distillation bridge. After three hours, 
a second portion of trimethyl orthoacetate was added (30.2 g, 0.251 mmol, 1.2 equiv) and 
the reaction mixture stirred at 110 °C for another four hours. The temperature was then 
raised to 135 °C and excess reagents distilled off the reaction mixture. Upon cooling, the 
mixture solidified. A mixture of water and methanol (75 mL, water/methanol 2/1) was 
added and the flask heated until the solid had completely dissolved. The hot solution was 
allowed to cool to room temperature and was stored at 8 °C to allow for crystallization of 
the product. Colorless crystals, yield: 62 %; m.p. = 97 °C; 1H NMR (400 MHz, CDCl3) δ 
3.99 (s, 3H), 3.78 (s, 3H), 2.62 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 184.6, 164.5, 115.1, 
85.8, 56.9, 52.3, 15.3; HRMS (ESI+) exact mass calculated for [C7H10NO3]+ m/z 156.0655 
[M+H]+, found m/z 156.0656; FT-IR ?̃? (neat, cm–1): 2957, 2222, 1715, 1572, 1470, 1438, 
1429, 1410, 1381, 1315, 1288, 1194, 1129, 1088, 1022, 969, 873, 788, 768, 641. Methyl 
(2Z,4E)-2-cyano-5-(dimethylamino)-3-methoxypenta-2,4-dienoate (23).[27] Methyl (Z)-
2-cyano-3-methoxybut-2-enoate (16.9 g, 0.109 mol, 1.0 equiv) was suspended in dry 
methanol (8 mL) under an inert atmosphere and N,N-dimethylformamide dimethylacetale 
(23.2 mL, 20.7 g, 0.174 mmol, 1.6 equiv) was added. The reaction mixture was stirred 
under reflux conditions for 45 min and turned dark red. Excess solvents and reagents 
were removed at the rotary evaporator. The red solid was dissolved in DCM and purified 
by filtration over a silica gel column. After evaporation of the solvent, the orange product 
was recrystallized from ethyl acetate/petroleum ether to give a bright yellow solid. Yellow 
crystals, yield: 74 %; m.p. = 129 °C; Rf = 0.27 (50 % EtOAc in pentane); 1H NMR (400 
MHz, CDCl3) δ 7.45 (d, J = 12.4 Hz, 1H), 6.09 (s, br, 1H), 3.93 (s, 3H), 3.65 (s, 3H), 3.13 
(s, 3H), 2.90 (s, 3H, NCH3)2); 13C NMR (101 MHz, CDCl3) δ 181.8 ((H3CO)C=C), 166.4 
(COOCH3), 153.3 (C=C(NMe2)), 119.3 (CN), 91.4 ((Me2N)C=C), 74.9 (C=C(CN)), 62.5 
(OCH3), 51.3 (COOCH3), 45.7 (N(CH3)2), 37.5 (N(CH3)2); HRMS (ESI+) exact mass 
calculated for [C10H15N2O3]+ m/z 211.1077 [M+H]+, found m/z 211.1074; FT-IR ?̃? (neat, 
cm–1): 2927, 2917, 2187 (CN), 1690, 1612, 1525, 1459, 1432, 1389, 1359, 1315, 1265, 
1225, 1205, 1185, 1133, 1052, 1000, 982, 891, 871, 823, 794, 769, 726, 643. Methyl 4-
methoxy-2-oxo-1,2-dihydropyridine-3-carboxylate. Methyl 2-cyano-5-(dimethyl-
amino)-3-methoxypenta-2,4-dienoate (15.1 g, 71.9 mmol) was dissolved in an aqueous 
solution of acetic acid (80 vol.-%, 50 ml) in a 250 ml round-bottomed flask and stirred 
under reflux conditions under inert gas for one hour. The dark red reaction mixture was 
diluted with water (25 ml) and solid sodium carbonate was carefully added until pH 7 was 
reached. The product was extracted from the aqueous phase with ethyl acetate (8 x 50 
mL) and with DCM (4 x 50 mL). The combined organic phases (red) were dried over 
sodium sulfate. After filtration of the drying agent the solvent was removed under vacuum. 
Flash chromatography yielded the product as an orange solid (7.7 % MeOH in DCM). 
Orange crystals, yield: 40 %; m.p. = 202–204 °C (decomposition); Rf = 0.29 (9.1 % MeOH 
in DCM); 1H NMR (400 MHz, CDCl3) δ 13.47 (s, 1H), 7.50 (d, J = 7.4 Hz, 1H), 6.15 (d, J 
= 7.5 Hz, 1H), 3.89 (s, 3H), 3.88 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 167.5, 165.5, 
163.8, 138.3, 108.4, 95.0, 56.7, 52.6; HRMS (ESI+) exact mass calculated for 
[C8H9NO4Na]+ m/z 206.0424 [M+Na]+, found m/z 206.0425; FT-IR ?̃? (neat, cm–1): 2952, 
2839, 2360, 1733, 1632, 1610, 1552, 1477, 1429, 1327, 1272, 1241, 1181, 1124, 1094, 
1073, 966, 952, 919, 836, 786, 770, 674, 629. Methyl 5-bromo-4-methoxy-2-oxo-1,2-
dihydropyridine-3-carboxylate (24). In a 100 ml round-bottomed flask, methyl 4-
methoxy-2-oxo-1,2-dihydropyridine-3-carboxylate (5.73 g, 31.3 mmol, 1.0 equiv) was 
suspended in acetonitrile (50 ml). NBS (5.57 g, 13.1 mmol, 1.0 equiv; freshly crystallized 
from water and dried under high vacuum) and ammonium nitrate (0.25 mg, 1.37 mmol, 
0.1 equiv) were added. The reaction mixture was heated to reflux for 45 min. The solvent 
was removed under vacuum. Ethyl acetate was added (80 ml), but the orange solid did 
not completely dissolve. Thus, the solid was filtered and dissolved in DCM. After 
evaporation of DCM, the pure product was obtained. The red solution of EtOAc was 
washed with brine (4 x 100 ml) and the combined organic phases were dried over sodium 
sulfate. After filtration of the drying agent, the solvent was removed under vacuum. The 
red solid residue partly dissolved in EtOAc and the solution overlain by toluene for 
recrystallization to give the product as slightly yellow crystals. The part of the red solid that 
was completely insoluble in EtOAc was collected by filtration and subjected to column 
chromatography (7.7 % MeOH in DCM). Slightly yellow crystals, yield: 96 %; m.p. = 
154 °C (decomposition); Rf = 0.39 (7.7 % MeOH in DCM); 1H NMR (400 MHz, CDCl3) δ 
13.27 (s, 1H), 7.59 (s, 1H), 3.99 (s, 3H), 3.93 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 165.6, 
163.9, 163.2, 137.2, 111.2, 96.5, 59.9, 53.2; HRMS (ESI+) exact mass calculated for 
[C8H8(79Br)NO4Na]+ m/z 283.9529 [M+Na]+, found m/z 283.9528; FT-IR ?̃? (neat, cm–1): 
3005, 2951, 2900, 2809, 2774, 2686, 1728, 1618, 1475, 1464, 1448, 1432, 1391, 1317, 
1266, 1246, 1212, 1099, 1070, 984, 959, 877, 860, 778, 766, 746, 692, 674. Methyl 5-
bromo-4-methoxy-2-oxo-1-{[2-(trimethylsilyl)ethoxy]methyl}-1,2-dihydropyridine-3-
carboxylate (25a).[12] To an ice-cooled solution of methyl 5-bromo-4-methoxy-2-oxo-1,2-
dihydropyridine-3-carboxylate (2.989 g, 11.40 mmol, 1.0 equiv) in dry DCM (24 mL), 2-
(trimethylsilyl)ethoxymethyl chloride (2.4 mL, 14 mmol, 1.2 equiv) and freshly distilled 
triethylamine (2.1 mL, 15 mmol, 1.3 equiv) were added. The reaction mixture was stirred 
at 0 °C for ten minutes and then further stirred at room temperature for four hours. The 
reaction mixture was diluted with DCM and washed with brine (200 mL). The aqueous 
phase was extracted with DCM (2 x 200 mL). The combined organic phases were dried 
over sodium sulfate, filtered and dried in vacuo. The product mixture was subjected to 
column chromatography (gradient: Et2O in pentane 25 % to 33 %). Colorless waxy solid, 
yield: 40 % (O-SEM product: 33 %); m.p. = 60–62 °C; Rf: 0.39 (6.3 % MeOH in DCM); 1H 
NMR (500 MHz, CDCl3) δ 7.61 (s, 1H), 5.26 (s, 2H), 3.99 (s, 3H), 3.92 (s, 3H), 3.62 (m, 
2H,), 0.98–0.88 (m, 2H), 0.00 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 165.7, 161.5, 160.9, 
137.1, 111.0, 95.9, 76.4, 67.8, 59.6, 53.2, 18.1, –1.3; HRMS (ESI+) exact mass calculated 
for [C14H22BrNNaO5Si]+ m/z 414.0343 [M(79Br)+Na]+, found m/z 414.0340, [M(79Br)+Na]+; 
FT-IR ?̃? (neat, cm–1): 2952, 2895, 1733, 1645, 1605, 1544, 1462, 1388, 1323, 1249, 1220, 
1141, 1082, 992, 916, 835, 757, 689, 623. Methyl 4-methoxy-5-{4-[(4-methoxybenzyl)-
oxy]phenyl}-2-oxo-1-{[2-(trimethylsilyl)ethoxy]methyl}-1,2-dihydropyridine-3-car-
boxylate (26).[12] A 25 mL Schlenk tube was loaded with ethyl 5-bromo-4-methoxy-2-oxo-
1-{[2-(trimethylsilyl)ethoxy]methyl}-1,2-dihydropyridine-3-carboxylate (1.764 g, 4.496 
mmol, 1.0 equiv), K2CO3 (1.865 g, 13.494 mmol, 3.0 equiv), [Pd(PPh3)4] (520 mg, 0.450 
mmol, 0.1 equiv) and {4-[(4-methoxybenzyl)oxy]phenyl}boronic acid (1.743 g, 6.754 
mmol, 1.5 equiv). The previously degassed solvent mixture (DME/water/DMF 9/1/0.5; 9 
mL) was added. The suspension was frozen in liquid nitrogen and was degassed in three 
freeze-pump-thaw-cycles. The reaction was then stirred for 16 hours at 60 °C. The 
reaction mixture was diluted with EtOAc (100 mL), washed with a saturated aqueous 
solution of ammonium chloride (1 x 100 mL) and with brine (2 x 100 mL). The organic 
phase was dried over sodium sulfate, filtered and the solvents were removed in vacuo. 
The crude product was purified by column chromatography (25 % pentane in diethyl ether 
+ 0.1 % Et3N). Colorless solid, yield: 92 %; Rf = 0.20 (25 % pentane in diethyl ether + 0.1 
% Et3N); 1H NMR (500 MHz, CDCl3) δ 7.37 (m, 2H, 7.34 (s, 1H), 7.33 (m, 2H), 6.99 (m, 
2H), 6.93 (m, 2H), 5.33 (s, 2H), 5.01 (s, 2H), 3.94 (s, 3H), 3.82 (s, 3H), 3.73 (s, 3H), 3.67 
(m, 2H), 0.95 (m, 2H), 0.00 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 166.6, 164.0, 161.2, 
159.7, 158.7, 136.1, 130.3, 129.4, 128.8, 126.2, 116.7, 115.0, 114.2, 111.6, 76.3, 70.0, 
67.6, 59.4, 55.4, 53.0, 18.2, –1.2; HRMS (ESI+) exact mass calculated for [C28H36NO7Si]+ 
m/z 526.2256 [M+H]+, found m/z 526.2256, [M+H]+; FT-IR ?̃? (neat, cm–1): 2955, 1733, 
1612, 1587, 1561, 1518, 1462, 1448, 1401, 1389, 1366, 1330, 1308, 1266, 1247, 1208, 
1166, 1079, 1056, 1036, 1007, 96, 976, 958, 904, 856, 832, 815, 753, 692, 668, 637. 
General Procedure for the Pyridone Methyl Ester Transesterification[28] 
A two-necked flask equipped with an adapter piece featuring a Por2 frit was filled with 
molecular sieves (4 Å), thoroughly flame-dried and flushed with argon. The flask was 
charged with 4-methoxy-5-{4-[(4-methoxybenzyl)oxy]phenyl}-2-oxo-1-{[2-(trimethylsilyl)-
ethoxy]methyl}-1,2-dihydro pyridine-3-carboxylate (1.0 equiv) and LiBr (5–6 equiv). Then, 
the flask was evacuated under high vacuum and flushed with argon. The solvent mixture 
(25 % DCM in THF, 0.1 M with respect to the pyridone methyl ester derivative) was added 
and the solution was stirred for 15 min. The alcohol (1.8–2.5 equiv) and DBU (0.5 equiv) 
were added over a septum via a syringe and the reaction mixture was heated to reflux 
under an atmosphere of argon for eight to nine hours. DCM and a saturated aqueous 
solution of ammonium chloride were added to the reaction mixture. The phases were 
separated and the aqueous phase was extracted with DCM (3 x 50 mL). The combined 
organic phases were dried over sodium sulfate. After filtration of the drying agent, the 
solvents were removed in vacuo. Preparative HPLC (method 1) was carried out to obtain 
the corresponding pyridone ester derivative. 
Pent-4-en-1-yl 4-hydroxy-5-{4-[(4-methoxybenzyl)oxy]phenyl}-2-oxo-1-{[2-(tri-
methyl silyl)ethoxy]methyl}-1,2-dihydropyridine-3-carboxylate (27). Colorless solid, 
yield: 22%, m.p. = 83 °C; Rf = 0.52 (25 % pentane in Et2O); 1H NMR (500 MHz, CDCl3) 
δ 14.12, 7.54 (s, 1H), 7.39 (m, 2H), 7.36 (m, 2H), 7.01 (m, 2H), 6.92 (m, 2H), 5.88 (ddt, 
J = 17.0, 10.2, 6.6 Hz, 1H), 5.29 (s, 2H), 5.08 (dd, J = 17.0, 1.6 Hz, 1H), 5.02 (s, 2H), 5.00 
(m, 1H), 4.38 (t, J = 6.7 Hz, 2H), 3.81 (s, 3H), 3.60 (m, 2H), 2.20 (m, 2H), 1.89 (m, 2H), 
0.93 (m, 2H), 0.00 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 173.8, 173.0, 159.8, 159.7, 
158.8, 140.1, 137.5, 130.4, 129.4, 128.9, 125.4, 115.5, 115.0, 114.2, 114.1, 98.6, 76.4, 
70.0, 67.5, 65.6, 55.5, 30.1, 27.7, 18.2, –1.2; HRMS (ESI+) exact mass calculated for 
[C31H40NO7Si]+ m/z 566.2569 [M+H]+, found m/z 566.2563, [M+H]+; FT-IR ?̃? (neat, cm–1): 
3075, 2998, 2952, 2901, 2880, 1731, 1665, 1612, 1515, 1468, 1446, 1406, 1347, 1323, 
1300, 1283, 1241, 1218, 1178, 1140, 1080, 1032, 1007, 974, 944, 920, 833, 823, 762, 
744, 708, 693, 650, 641, 611. Decyl 4-hydroxy-5-{4-[(4-methoxybenzyl)oxy]phenyl}-
2-oxo-1-{[2-(trimethylsilyl)ethoxy] methyl}-1,2-dihydropyridine-3-carboxylate (28). 
Colorless solid, yield: 28 %; Rf = 0.70 (4.8 % MeOH in DCM); 1H NMR (500 MHz, CDCl3) 
δ 14.18 (s, 1H), 7.54 (s, 1H), 7.37 (m, 2H), 7.36 (dd, J = 2.2, 1.5 Hz, 2H), 7.08–6.96 (m, 
2H), 6.91 (m, 2H), 5.34 (s, 2H), 5.02 (s, 2H), 4.40 (t, J = 7.1 Hz, 2H), 3.82 (s, 3H), 3.69–
3.64 (m, 2H), 1.85 (m, 2H), 1.47–1.40 (m, 2H), 1.38–1.23 (m, 12H), 1.00–0.93 (m, 2H), 
0.88 (t, J = 7.0 Hz, 3H), 0.01 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 173.8, 173.0, 159.7, 
159.6, 158.7, 140.0, 130.3, 129.3, 128.9 , 125.4, 114.9, 114.1, 114.0, 98.5, 76.3, 70.0, 
67.4, 66.3, 55.4, 32.0, 29.7, 29.6, 29.4, 29.4, 28.7, 25.9, 22.8, 18.2, 14.2, –1.3; HRMS 
(ESI+) exact mass calculated for [C36H52NO7Si+] m/z 638.3508 [M+H]+, found m/z 
638.3507, [M+H]+. 
General Procedure for N-SEM Deprotection of Pyridone Derivatives[12] 
To a solution of the N-SEM protected pyridone ester in THF (dry, 0.1 M) was added a 
solution of TBAF in THF (dry, 1 M, 2.2 equiv) via syringe. The reaction mixture was heated 
to 65 °C for 48 hours. The reaction mixture was concentrated in vacuo, diluted with DCM 
and poured on brine/DCM. The phases were separated and the aqueous phase was 
extracted with DCM. The combined organic phases were dried over sodium sulfate. After 
filtration of the drying agent, the solvent was evaporated in vacuo. The crude product was 
suspended in cold MeOH (–20 °C). The solvent was removed via a teflon cannula with a 
filter paper attached to it by teflon tape, and rinsed with cold MeOH to obtain the pure 
compound. 
Pent-4-en-1-yl 4-hydroxy-5-{4-[(4-methoxybenzyl)oxy]phenyl}-2-oxo-1,2-dihydropy-
ridine-3-carboxylate. Colorless solid, yield: 81%; m.p. = 192 °C; Rf = 0.18 (25 % pentane 
in Et2O); 1H NMR (400 MHz, CDCl3): δ 14.01 (s, 1H), 12.64 (s, 1H), 7.47 (s, 1H), 7.41–
7.32 (m, 4H), 7.04 (m, 2H), 6.92 (m, 2H), 5.85 (ddt, J = 16.9, 10.2, 6.6 Hz, 1H), 5.16–4.96 
(m, 4H), 4.43 (t, J = 6.9 Hz, 2H), 3.82 (s, 3H), 2.15 (m, 2H), 1.93 (m, 2H); 13C NMR (101 
MHz, CDCl3): δ 174.3, 172.5, 162.8, 159.6, 158.7, 138.8, 137.5, 130.3, 129.4, 129.0, 
125.3, 115.6, 115.0, 114.4, 114.2, 98.8, 65.6, 55.4, 30.1, 27.8; the 13C signal of C12H2 was 
not observed; HRMS (ESI+) exact mass calculated for [C25H26NO6]+ m/z 436.1755 
[M+H]+, found m/z 436.1748 [M+H]+; FT-IR ?̃? (neat, cm–1): 2975, 2911, 2845, 2758, 1647, 
1549, 1514, 1487, 1451, 1412, 1382, 1351, 1307, 1277, 1236, 1206, 1178, 1080, 1022, 
971, 889, 826, 764, 729, 610. Decyl 4-hydroxy-5-{4-[(4-methoxybenzyl)oxy]phenyl}-
2-oxo-1,2-dihydropyridine-3-carboxylate. Colorless solid, yield: 53 %; Rf = 0.17 (4.8 % 
MeOH in DCM); 1H NMR (500 MHz, CDCl3) δ 14.07 (s, 1H), 12.21 (s, 1H), 7.45 (s, 1H), 
7.41–7.37 (m, 4H), 7.35 (m, 2H), 5.02 (s, 2H), 4.41 (t, J = 7.1 Hz, 2H), 3.83 (s, 3H), 1.84 
(m, 2H), 1.45 (m, 2H), 1.37–1.13 (m, 12H), 0.86 (t, J = 7.0 Hz, 3H); 13C NMR (126 MHz, 
CDCl3) δ 174.3, 172.6, 162.6, 159.7, 158.8, 138.6, 130.4, 129.4, 129.0, 125.3, 115.0, 
114.4, 114.2, 98.9, 70.0, 66.4, 55.5, 32.0, 29.7, 29.7, 29.4, 29.4, 28.7, 26.0, 22.8, 14.3; 
FT-IR ?̃? (neat, cm-1): 2921, 2834, 1725, 1680, 1634, 1552, 1515, 1466, 1441, 1410, 1346, 
1278, 1243, 1178, 1078, 1037, 956, 873, 829, 742, 652, 612. 
General Procedure for PMB Deprotection of Pyridone Ester Derivatives[12] 
To an ice-cooled solution of PMB-protected pyridone ester derivative in DCM (0.2 M) was 
added a solution of TFA in DCM (2.5 weight-%, 15 equiv). The reaction mixture was stirred 
with cooling for 30 minutes and then allowed to warm to room temperature (45–60 
minutes). The reaction mixture was diluted with DCM and poured on brine. The phases 
were separated and the aqueous phase was extracted with DCM. The organic phases 
were dried over sodium sulfate. After filtration of the drying agent, the solvent was 
removed in vacuo. The resulting colorless solid was purified via flash chromatography 
(6.3 % MeOH in DCM). 
Pent-4-en-1-yl 4-hydroxy-5-(4-hydroxyphenyl)-2-oxo-1,2-dihydropyridine-3-carboxy-
late (9). Colorless solid, yield: 48 %; m.p. = 225–230 °C (decomposition); Rf = 0.15 (6.3 % 
MeOH in DCM); 1H NMR (400 MHz, CD3OD) δ 7.47 (s, 1H), 7.32–7.23 (m, 2H), 6.81 (m, 
2H), 5.87 (ddt, J = 17.0, 10.2, 6.7 Hz, 1H), 5.03 (m, 2H), 4.39 (t, J = 6.7 Hz, 2H), 2.25 (m, 
2H), 1.89 (m, 2H); 13C NMR (101 MHz, CD3OD) δ 175.4, 173.5, 162.8, 158.3, 139.8, 138.9, 
131.4, 125.3, 116.1, 115.7, 101.4, 66.3, 31.1, 28.8; HRMS (ESI+) exact mass calculated for 
[C17H18NO5]+ m/z 316.1179 [M+H]+, found m/z 316.1176, [M+H]+;	FT-IR ?̃? (neat, cm–1): 3214, 
2987–2757, 1650, 1540, 1513, 1484, 1443, 1418, 1343, 1303, 1276, 1249, 1202, 1175, 
1110, 1081, 994, 950, 910, 870, 836, 724, 678. Decyl 4-hydroxy-5-(4-hydroxyphenyl)-2-
oxo-1,2-dihydropyridine-3-carboxylate (10). Colorless solid, yield: 62 %; m.p. = 190 °C; 
Rf = 0.10 (6.3 % MeOH in DCM); 1H NMR (500 MHz, CD3OD) δ 7.45 (s, 1H), 7.28 (m, 2H), 
6.81 (m, 2H), 4.37 (t, J = 6.8 Hz, 2H), 1.79 (m, 2H), 1.55 (m, 2H), 1.37 (m, 12H), 0.90 (m, 
3H); 13C NMR (101 MHz, CD3OD) δ 175.5, 173.5, 162.8, 158.3, 139.7, 131.4, 125.4, 116.1, 
99.9, 66.9, 33.1, 30.7, 30.7, 30.5, 30.4, 29.6, 27.0, 23.7, 14.4; HRMS (ESI+) exact mass 
calculated for [C22H30NO5]+ m/z 388.2118 [M+H]+, found m/z 388.2119, [M+H]+; FT-IR ?̃? 
(neat, cm–1): 3271 , 2923, 2852, 2439 , 2287, 1640, 1543, 1513, 1470, 1423, 1343, 1310, 
1244, 1192, 1106, 1076, 1002, 896, 837, 720, 653. 
 
General Procedure for Regioselective Lithiation and Alkylation of 3,5-Dibromo-2,4-
dimethoxypyridine[9] 
In a flame-dried two-necked flask, 3,5-dibromo-2,4-dimethoxypyridine (1.0 equiv) was 
dissolved in dry THF (0.1 M with respect to the 3,5-dibromo-2,4-dimethoxypyridine). This 
solution was then cooled down to –78 °C and a previously titrated s-BuLi solution (1.35 M 
in cyclohexane, 1.0–1.2 equiv) was added dropwise over 10–15 minutes. The mixture was 
stirred for one hour at –78 °C. A solution of the aldehyde in dry THF (1.2 M, 1.0–2.5 equiv) 
was slowly added. The mixture was stirred for another hour at -78 °C. The mixture was 
then allowed to warm to room temperature with continued stirring (14–16 hours). The 
mixture was quenched with water (1/3 of the volume of THF). A saturated aqueous 
ammonium chloride solution (1/3 of the volume of THF) and ethyl acetate (two times the 
volume of THF) were added. The phases were separated and the aqueous phase was 
extracted with ethyl acetate. The combined organic phases were washed with brine and 
dried over magnesium sulfate. After filtration of the drying agent, the solvents were 
removed in vacuo. The crude product was purified by flash chromatography (7 % ethyl 
acetate in pentane). 
1-(5-Bromo-2,4-dimethoxypyridin-3-yl)octan-1-ol (31). Colorless liquid, yield: 69%; Rf 
= 0.15 (7% ethyl acetate in pentane); 1H NMR (250 MHz, CDCl3) δ 8.12 (s, 1H), 4.93 (m, 
1H), 3.96 (s, 3H), 3.91 (s, 3H), 3.21 (d, J = 11.5 Hz, 1H), 1.94–1.81 (m, 1H), 1.69–1.63 
(m, 1H), 1.26 (m, 10H), 0.86 (t, J = 6.7 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 162.2, 
162.0, 147.8, 121.3, 108.1, 67.9, 61.8, 54.1, 37.3, 32.0, 29.5, 29.3, 26.3, 22.8, 14.2; 
HRMS (ESI+) exact mass calculated for [C15H25O3NBr]+ m/z 346.10123 [M(79Br)+H]+, 
found m/z 346.1012 [M(79Br)+H]+; FT-IR ?̃? (neat, cm-1): 3568, 3446, 2925, 2855, 1729, 
1564 1458, 1416, 1381, 1297, 1250, 1160, 1086, 1008, 914, 832, 794, 723, 663, 624. 1-
(5-Bromo-2,4-dimethoxypyridin-3-yl)dodecan-1-ol (32). Colorless oil, yield: 93 %; Rf 
= 0.17 (7 % ethyl acetate in pentane); 1H NMR (400 MHz, CDCl3) δ 8.13 (s, 1H), 4.95–
4.92 (m, 1H), 3.97 (s, 3H), 3.91 (s, 3H), 3.20 (bs, 1H), 1.89 (m, 1H), 1.70 (m, 1H), 1.48 
(m, 1H), 1.32–1.21 (m, 17H), 0.87 (t, J = 6.8 Hz, 3H); HRMS (ESI+) exact mass calculated 
for [C19H33BrNO3]+ m/z 402.16383 [M(79Br)+H]+, found m/z 402.1639 [M(79Br)+H]+; FT-
IR ?̃? (neat, cm–1): 3572, 3436, 2923, 2853, 1729, 1564 1459, 1416, 1381, 1298, 1250, 
1162, 1089, 1009, 914, 826, 794, 664, 630. 1-(5-Bromo-2,4-dimethoxypyridin-3-
yl)octadecan-1-ol (33). Colorless solid, yield: 77 %; m.p.= 52 °C; Rf = 0.24 (7 % ethyl 
acetate in pentane); 1H NMR (400 MHz, CDCl3) δ 8.11 (s, 1H), 4.995–4.89 (m, 1H), 3.94 
(s, 3H), 3.89 (s, 3H), 3.19 (d, J = 11.2 Hz, 1H), 1.94–1.81 (m, 1H), 1.70–1.61 (m, 1H), 
1.33–1.17 (m, 30H), 0.85 (t, J = 6.8 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 162.1, 162.0, 
147.7, 121.3, 108.1, 67.8, 61.7, 54.1, 37.3, 32.0, 29.8, 29.8, 29.8, 29.7, 29.7, 29.5, 29.5, 
26.3, 22.8, 14.2; HRMS (ESI+) exact mass calculated for [C25H45BrNO3]+ m/z 486.25773 
[M(79Br)+H]+, found m/z 486.2576 [M(79Br)+H]+; FT-IR ?̃? (neat, cm–1): 3440, 3297, 2919, 
2851, 1565 1461, 1416, 1381, 1297, 1251, 1119, 1089, 1012, 936, 910, 844, 794, 665, 
628. 
General Procedure for Suzuki Cross-Coupling Reactions[9] 
A flame-dried Schlenk tube was charged with 5-bromo-2,4-dimethoxypyridine (1.0 equiv), 
4-[(tert-butyldimethylsilyl)oxy]phenyl boronic acid (1.8–2.0 equiv) and [Pd(PPh3)4] (8 
mol%). The flask was evacuated and flushed with argon. A degassed mixture of 
toluene/ethanol (20 % ethanol in toluene, 0.05 M with respect to the 5-bromo-2,4-
dimethoxypyridine) and a degassed aqueous solution of sodium carbonate (2 M, 70 Vol-
% of the organic solvent) were added. The reaction mixture was heated to reflux (85 °C) 
for 14–20 hours. Ethyl acetate was added and the phases were separated. The organic 
phase was washed with water and brine, and dried over anhydrous magnesium sulfate. 
After filtration of the drying agent, the solvent was removed in vacuo. The crude product 
was purified by column chromatography (7 % ethyl acetate in pentane).  
1-{5-[4-((tert-Butyldimethylsilyl)oxy)phenyl]-2,4-dimethoxypyridin-3-yl}octan-1-ol 
(34). Colorless liquid, yield: 94 %; Rf = 0.07 (7 % ethyl acetate in pentane); 1H NMR (400 
MHz, CDCl3) δ 7.96 (s, 1H), 7.38–7.29 (m, 2H), 6.94–6.86 (m, 2H), 5.03 (ddd, J = 11.6, 
8.4, 5.8 Hz, 1H), 4.01 (s, 3H), 3.42 (d, J = 11.6 Hz, 1H), 3.39 (s, 3H), 1.97–1.84 (m, 1H), 
1.78–1.68 (m, 1H), 1.59–1.46 (m, 1H), 1.35–1.24 (m, 8H), 1.00 (s, 9H), 0.88 (t, J = 6.8 
Hz, 3H), 0.23 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 163.2, 161.7, 155.4, 146.8, 130.0, 
128.5, 124.9, 120.4, 118.6, 67.8, 60.8, 53.8, 37.8, 32.0, 29.6, 29.4, 26.4, 25.8, 22.8, 18.4, 
14.3, -4.2; HRMS (ESI+) exact mass calculated for C27H44NO4Si m/z 474.30341 [M+H]+, 
found m/z 474.3040 [M+H]+; FT-IR ?̃? (neat, cm–1): 3568, 3462, 2929, 2857, 1589, 1513, 
1467, 1413, 1377, 1255, 1171, 1136 1072, 1012, 911, 840, 806, 781, 657, 624. 1-{5-[4-
((tert-Butyldimethylsilyl)oxy)phenyl]-2,4-dimethoxypyridin-3-yl}dodecan-1-ol (35). 
Colorless liquid, yield: 94 %; Rf = 0.09 (7 % ethyl acetate in pentane); 1H NMR (400 MHz, 
CDCl3) δ 7.96 (s, 1H), 7.38–7.30 (m, 2H), 6.96–6.84 (m, 2H), 5.03 (ddd, J = 11.6, 8.3, 5.8 
Hz, 1H), 4.01 (s, 3H), 3.42 (d, J = 11.6 Hz, 1H), 3.39 (s, 3H), 1.96–1.85 (m, 1H), 1.77–
1.66 (m, 1H), 1.53 (m, 1H), 1.38–1.20 (m, 17H), 1.00 (s, 9H), 0.87 (t, J = 6.7 Hz, 3H), 0.23 
(s, 6H); 13C NMR (101 MHz, CDCl3) δ 163.2, 161.7, 155.4, 146.8, 130.0, 128.5, 124.9, 
120.4, 118.6, 67.8, 60.8, 53.8, 37.8, 32.1, 29.8, 29.8, 29.8 29.7, 29.5, 26.4, 25.8, 22.8, 
18.4, 14.3, -4.2; HRMS (ESI+) exact mass calculated for [C31H52NO4Si]+ m/z 530.36601 
[M+H]+, found m/z 530.3666 [M+H]+; FT-IR ?̃? (neat, cm-1): 3566, 2927, 2852, 1590, 1514, 
1468, 1423, 1377, 1258, 1171, 1136 1073, 1013, 912, 842, 782, 735, 688, 632. 1-{5-[4-
((tert-Butyldimethylsilyl)oxy)phenyl]-2,4-dimethoxypyridin-3-yl}octadecan-1-ol 
(36). Colorless solid, yield: 93 %, m.p. = 48 °C; Rf = 0.10 (7 % ethyl acetate in pentane); 
1H NMR (500 MHz, CDCl3) δ 7.96 (s, 1H), 7.38–7.29 (m, 2H), 6.94–6.85 (m, 2H), 5.03 
(ddd, J = 11.6, 8.3, 5.8 Hz, 1H), 4.01 (s, 3H), 3.41 (d, J = 11.6 Hz, 1H), 3.39 (s, 3H), 1.95–
1.86 (m, 1H), 1.75 -1.68 (m, 1H), 1.56–1.47 (m, 1H), 1.35–1.23 (m, 29H), 1.00 (s, 9H), 
0.88 (t, J = 6.9 Hz, 3H), 0.23 (s, 6H); 13C NMR (126 MHz, CDCl3) δ 163.2, 161.7, 155.4, 
146.8, 130.0, 128.5, 124.9, 120.4, 118.6, 67.8, 60.8, 53.8, 37.9, 32.1, 29.9, 29.9, 29.8, 
29.8, 29.8, 29.7, 29.5, 26.4, 25.8, 22.9, 18.4, 14.3, –4.2; HRMS (ESI+) exact mass 
calculated for C37H64NO4Si m/z 614.45991 [M+H]+, found m/z 614.4609 [M+H]+; FT-IR ?̃? 
(neat, cm–1): 3574, 2924, 2854, 1590, 1514, 1468, 1423, 1377, 1258, 1171, 1135 1073, 
1014, 913, 842, 806 782, 719, 632. 
General Procedure for Dess-Martin Oxidation[9] 
The racemic mixture of secondary pyridine alcohol (1.0 equiv) was dissolved in dry DCM 
(0.02 M) and Dess-Martin periodinane (1.5–1.8 equiv) was added portionwise. The 
colorless suspension was stirred at room temperature until completion of the reaction (1–
2 hours). The reaction mixture was quenched with a saturated aqueous solution of sodium 
hydrogen carbonate and ethyl acetate. The mixture was treated with solid sodium 
thiosulfate (300 mg per 100 mg of Dess-Martin periodinane) and stirred until the 
precipitate was dissolved. The phases were separated and the aqueous phase was 
extracted with ethyl acetate. The combined organic phases were dried over magnesium 
sulfate and the solvent was removed in vacuo. The product was purified by elution through 
a short silica gel column (7 % ethyl acetate in petroleum ether). 
1-{5-[4-((tert-Butyldimethylsilyl)oxy)phenyl]-2,4-dimethoxypyridin-3-yl}octan-1-
one. Colorless oil, yield: 92 %; Rf = 0.46 (7 % ethyl acetate in petroleum ether); 1H NMR 
(400 MHz, CDCl3) δ 8.06 (s, 1H), 7.33 (d, J = 8.6 Hz, 2H), 6.90 (d, J = 8.6 Hz, 2H), 3.96 
(s, 3H), 3.44 (s, 3H), 2.81 (t, J = 7.4 Hz, 2H), 1.70 (p, J = 7.4 Hz, 2H), 1.39–1.24 (m, 8H), 
1.00 (s, 9H), 0.92–0.86 (m, 3H), 0.23 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 203.9, 162.7, 
160.6, 155.6, 148.7, 130.1, 127.8, 124.6, 120.4, 118.2, 61.4, 54.1, 44.9, 31.9, 29.3, 29.2, 
25.8, 23.7, 22.8, 18.4, 14.2, –4.2; HRMS (ESI+) exact mass calculated for [C27H42NO4Si]+ 
m/z 472.28776 [M+H]+, found m/z 472.2879 [M+H]+; FT-IR ?̃? (neat, cm–1): 2930, 2858, 
1708, 1588, 1513, 1467, 1409, 1378, 1259, 1172, 1142, 1110 1085, 1009, 913, 841, 782, 
668, 632. 1-{5-[4-((tert-Butyldimethylsilyl)oxy)phenyl]-2,4-dimethoxypyridin-3-yl}-
dodecan-1-one. Colorless oil, yield: 82 % ; Rf = 0.48 (7 % ethyl acetate in pentane); 1H 
NMR (400 MHz, CDCl3) δ 8.06 (s, 1H), 7.37–7.29 (m, 2H), 6.94–6.85 (m, 2H), 3.96 (s, 
3H), 3.44 (s, 3H), 2.81 (t, J = 7.4 Hz, 2H), 1.75–1.64 (m, 2H), 1.28 (m, 16H), 1.04–0.94 
(m, 9H), 0.87 (t, J = 6.8 Hz, 3H), 0.23 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 203.9, 162.7, 
160.5, 155.6, 148.7, 130.1,127.8, 124.6, 120.4,118.2, 61.4, 54.0, 44.9, 32.1, 29.8, 29.8, 
29.7, 29.6, 29.5, 29.3, 25.8, 23.7, 22.8, 18.4, 14.3, –4.2; HRMS (ESI+) exact mass 
calculated for [C31H50NO4Si]+ m/z 528.35036 [M+H]+, found m/z 528.3510 [M+H]+; FT-IR ?̃? 
(neat, cm–1): 2928, 2856, 1709, 1588, 1516, 1468, 1409, 1378, 1317, 1260, 1172, 1090 
1010, 913, 841, 782, 688, 632. 1-{5-[4-((tert-Butyldimethylsilyl)oxy)phenyl]-2,4-
dimethoxypyridin-3-yl}octadecan-1-one. Colorless solid, yield: 94 %, m.p.= 42 °C; Rf 
= 0.51 (7 % ethyl acetate in pentane); 1H NMR (400 MHz, CDCl3) δ 8.06 (s, 1H), 7.40–
7.30 (m, 2H), 6.94–6.84 (m, 2H), 3.96 (s, 3H), 3.44 (s, 3H), 2.81 (t, J = 7.4 Hz, 2H), 1.70 
(p, J = 7.4 Hz, 2H), 1.36–1.22 (m, 28H), 1.00 (s, 9H), 0.88 (t, J = 6.9 Hz, 3H), 0.23 (s, 6H); 
13C NMR (101 MHz, CDCl3) δ 203.9, 162.7, 160.5, 155.6, 148.7, 130.1, 127.8, 124.6, 
120.4, 118.2, 61.4, 54.0, 44.9, 32.1, 29.9, 29.8, 29.8, 29.7, 29.6, 29.5, 29.3, 25.8, 23.7, 
22.8, 18.4, 14.3, –4.2; HRMS (ESI+) exact mass calculated for [C37H62NO4Si]+ m/z 
612.4443 [M+H]+, found m/z 612.4433 [M+H]+; FT-IR ?̃? (neat, cm–1): 2919, 2851, 2361, 
1703, 1585, 1559, 1515, 1462, 1407, 1364, 1328, 1258, 1173, 1135 1107, 1076, 1005, 
914, 839, 806 780, 750, 719, 722, 704, 681, 654. 
General Procedure for Pyridine Deprotection[9] 
The protected pyridine (1.0 equiv) was dissolved in MeCN (dry, 0.01–0.02 M). Dry 
aluminium chloride (25 equiv) and dry sodium iodide (20 equiv) were added. The mixture 
was stirred at room temperature or 45 °C for one to two hours. The reaction mixture was 
quenched with a few milliliters of hydrochloric acid (1 M, aq) and extracted four times with 
ethyl acetate. The combined organic phases were washed with an aqueous solution of 
sodium thiosulfate (5 weight-%), brine and dried over magnesium sulfate. The solvent was 
removed in vacuo and the crude product was purified by preparative HPLC (MeCN/water). 
4-Hydroxy-5-(4-hydroxyphenyl)-3-octanoylpyridin-2(1H)-one (11). Colorless solid, 
yield: 68 %, m.p. = 154 °C; Rf = 0.29 (6.3 % methanol in DCM); 1H NMR (400 MHz, 
DMSO-d6) δ 11.67 (d, J = 6.5 Hz, 1H), 9.48 (s, 1H), 7.56 (d, J = 6.5 Hz, 1H), 7.30–7.19 
(m, 2H), 6.82–6.71 (m, 2H), 3.12 (t, J = 7.4 Hz, 2H), 1.58 (p, J = 7.0 Hz, 2H), 1.37–1.19 
(m, 8H), 0.90–0.81 (m, 3H); 13C NMR (101 MHz, DMSO-d6) δ 208.1, 175.3, 161.4, 156.7, 
140.7, 130.1, 123.3, 115.0, 112.2, 106.0, 41.9, 31.2, 28.7, 28.6, 23.9, 22.1, 13.9; HRMS 
(ESI+) exact mass calculated for [C19H24NO4]+ m/z 330.1700 [M+H]+, found m/z 330.1695 
[M+H]+; FT-IR ?̃? (neat, cm-1): 3295, 2925, 2854, 1659, 1607, 1542, 1512, 1453, 1427, 
1379, 1231, 1175, 1109, 988, 901, 833, 705, 635. 3-Dodecanoyl-4-hydroxy-5-(4-
hydroxyphenyl)pyridin-2(1H)-one (12). Colorless solid, yield: 78 %, m.p. = 162 °C; Rf 
= 0.30 (6.3 % methanol in DCM); 1H NMR (400 MHz, DMSO-d6) δ 11.67 (d, J = 5.7 Hz, 
1H), 9.48 (s, 1H), 7.56 (d, J = 5.7 Hz, 1H), 7.32–7.15 (m, 2H), 6.87–6.68 (m, 2H), 3.12 (t, 
J = 7.4 Hz, 2H), 1.58 (p, J = 7.0 Hz, 2H), 1.33–1.23 (m, 16H), 0.97–0.78 (m, 3H); 13C NMR 
(101 MHz, DMSO-d6) δ 208.1, 175.3, 161.4, 156.7, 140.7, 130.1, 123.3, 115.0, 112.2 , 
106.0, 41.9, 31.3, 29.0, 29.0, 28.9, 28.8, 28.7, 23.8, 22.1, 14.0; HRMS (ESI+) exact mass 
calculated for [C23H32NO4]+ m/z 386.2326 [M+H]+, found m/z 386.2330 [M+H]+; FT-IR ?̃? 
(neat, cm–1): 3540, 2923, 2851, 2339, 2210, 1652, 1605, 1537, 1512, 1457, 1420, 1381, 
1317, 1251, 1209, 1173, 1106, 1043, 980, 896, 832, 769, 703, 650. 4-Hydroxy-5-(4-
hydroxyphenyl)-3-stearoylpyridin-2(1H)-one (13). Colorless solid, yield: 78 %, m.p.= 
154 °C ; Rf = 0.32 (6.3 % methanol in DCM); 1H NMR (400 MHz, DMSO-d6) δ 11.67 (d, J 
= 6.5 Hz, 1H), 9.47 (s, 1H), 7.56 (d, J = 6.5 Hz, 1H), 7.33–7.14 (m, 2H), 6.84–6.72 (m, 
2H), 3.12 (t, J = 7.4 Hz, 2H), 1.58 (p, J = 7.0 Hz, 2H), 1.23 (m, 28H), 0.87–0.80 (t, J = 
6.5 Hz, 3H); 13C NMR (101 MHz, DMSO-d6) δ 208.1, 175.3, 161.4, 156.7, 140.7, 130.1, 
123.3, 115.0, 112.2, 106.0, 41.9, 31.3, 29.0, 28.9, 28.8, 28.7, 23.8, 22.1, 13.9; HRMS 
(ESI+) exact mass calculated for [C29H44NO4]+ m/z 470.3265 [M+H]+, found m/z 470.3267 
[M+H]+; FT-IR ?̃? (neat, cm–1): 3534, 2919, 2850, 2224, 1654, 1608, 1512, 1460, 1420, 
1235, 1174, 1106, 988, 895, 832, 722, 638. 
 
5.2 Biological Testing 
AEA, N-(2-hydroxyethyl-1,1,2,2-d4)-(5Z,8Z,11Z,14Z)-eicosatetraenamide, 2-AG, 2-
[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-5-(2-methyloctan-2-yl)phenol 
(CP55,940, 14), (5Z,8Z,11Z,14Z)-N-(3-furanylmethyl)-5,8,11,14-eicosatetraenamide 
(UCM707, 15),[18] 4-nitrophenyl-4-[bis(1,3-benzodioxol-5-yl)(hydroxy)methyl]piperidine-1-
carboxylate (JZL184, 16),[19] N-methyl-N-{[3-(4-pyridinyl)phenyl]methyl}-carbamic acid 4'-
(aminocarbonyl)(1,1'-biphenyl)-4-yl ester (WWL70, 17),[20] (S)-1-[(2S,3S)-3-hexyl-4-oxo-
oxetan-2-yl]tridecan-2-yl formyl-L-leucinate (tetrahydrolipstatin, THL, 18),[20] 
(5Z,8Z,11Z,14Z)-eicosatetraenoic acid, [3-(aminocarbonyl)(1,1-biphenyl)-3-yl]-cyclo-
hexylcarbamate (URB597, 19),[21] 5-bromo-2-(4-fluorophenyl)-3-[4-(methylsulfonyl)phe-
nyl]-thiophene (DuP697, 20),[22] (9Z)-N-[1-((R)-4-hydroxybenzyl)-2-hydroxyethyl]-9-
octadecenamide (OMDM-2, 21),[23] (11R)-2-methyl-11-[(morpholin-4-yl)methyl]-3-
(naphthalene-1-carbonyl)-9-oxa-1-azatricyclo[6.3.1.04,12]dodeca-2,4(12),5,7-tetraene 
(WIN55,212-2)[24] and methylarachidonylfluorophosphonate (MAFP)[39] were purchased 
from Cayman Chemicals Europe.[40] [Ethanolamine-1-3H]-AEA (60 Ci/mmol) and [1,2,3-
3H]2-AG (20–40 Ci/mmol) were obtained from American Radiolabeled Chemicals, Inc.. 
 
5.2.1 Cell Culture 
Human monocytic leukemia U937 cells were purchased from American Type Culture 
Collection (Manassas, VA) and were grown in RPMI 1640 medium supplemented with 
10% fetal bovine serum, 1 g/ml fungizone (amphotericin B), 100 units/ml penicillin, 100 
g/ml streptomycin, and 2 mM L-glutamine (all from Invitrogen).[41] Cells were grown in a 
humidified incubator at 37 °C and in humidified atmosphere with 5% CO2. 
5.2.2 CB1 and CB2 binding 
CB1 and CB2 receptor affinities were determined using [3H]CP55,940 (0.5 nM) as 
displacing ligand and membrane preparations of stably transfected hCB1 and hCB2 CHO-
K1 cells as previously described.[42] (R)-WIN55,212-2 was used as positive control (10 
µM)[24] to determine total specific binding. Compounds were screened in triplicates (10 
µM). Ki values were calculated using the Cheng-Prusoff equation (CP55,940 hCB1 Kd=0.5 
nM, hCB2 Kd=0.59 nM). 
5.2.3 FAAH, MAGL and ABHD activity assays  
FAAH and MAGL activity assays were performed using U937 cell homogenate and pig 
brain homogenate, respectively, as previously described.[36] ABHDs assay was performed 
using BV-2 cell homogenate as previously described.[43] Briefly, FAAH activity was 
assessed using 100 µg of U937 cell homogenate diluted in 200 µL of Tris–HCl 10 mM, 
EDTA 1 mM, pH 8 containing 0.1% fatty acid-free BSA. Compounds were added (2 µL) 
at the screening concentration of 10 µM and incubated for 30 min at 37 °C. Then, 100 nM 
of AEA-containing 1 nM of [ethanolamine-1-3H]AEA as a tracer was added to the 
homogenates and incubated for 15 min at 37 °C. The reaction was stopped by the addition 
of 400 µL of ice-cold CHCl3:MeOH (1:1), samples were vortexed and rapidly centrifuged 
at 16000 g for 10 min at 4 °C. The aqueous phases were collected and the radioactivity 
was measured for tritium content by liquid scintillation spectroscopy. MAGL activity was 
measured in a similar assay, but replacing U937 cell homogenate with 200 µg of pig brain 
homogenate and using [3H]2-oleoylglycerol ([3H]2-OG) as a substrate. The reaction was 
performed in presence of URB597 (1 µM)[21] in all samples to avoid the interference of 
FAAH activity on [3H]2-OG hydrolysis (approximately 10–20%). WWL70 (17) at 10 µM 
and THL (18) at 20 µM were used as positive controls for ABHD6 and ABHD12 inhibition, 
respectively.[20] JZL184 at 1 µM was used as positive control for MAGL inhibition.[19] 
 
5.2.4 COX-2 activity 
The experiments were performed as previously described.[32a] Briefly, the inhibition of 
recombinant hCOX-2 was assessed using a COX fluorescent inhibitor screening assay kit 
from Cayman Chemicals Europe. Tested compounds or vehicle were pre-incubated with 
COX-FIS assay buffer (Tris-HCl 100 mM, pH 8), 1 μM of COX-FIS heme hCOX-2 FIS 
assay agent, and 30 μM of ADHP (10-acetyl-3,7-dihydroxyphenoxazine) fluorometric 
substrate for 15 min at RT. The reaction was started by adding arachidonic acid or 2-
arachidonoyl glycerol (10 μM). Fluorescence intensity was measured at l = 535 nm/580 
nm after 5 min of incubation. The results were expressed as hCOX-2 activity. 
5.2.5 AEA uptake 
The uptake of [ethanolamine-1-3H]-AEA (60 Ci/mmol) in intact cells was investigated by 
using U937 cells as previously described.[16b] Briefly, approx. 106 cells were suspended in 
500 µL of serum-free medium in silanized plastic tubes and pre-incubated with a screening 
concentration (10  µM) of the compounds for 20 min at 37 °C. Hit compounds were tested 
at different concentrations in the concentration range 0.01–30 µM. Then, the cells were 
incubated for 5 min at 37 °C with 100 nM of AEA and a small tracer (0.5 nM) of [3H]AEA 
was added. The uptake process was stopped by transferring the tubes on ice and rapidly 
centrifuging them at 800 g for 5 min at 4 °C. The supernatants were discarded and the 
pellets were re-suspended in 250 µL of ice-cold PBS plus 1% fatty acid-free BSA and 
centrifuged at 800 g for 5 min at 4 °C (washing step). The washing solution was discarded 
and cell pellets were re-suspended in 250 µL of ice-cold PBS and transferred into 500 µL 
of a CHCl3:MeOH mixture (1:1, v/v), vortexed vigorously, sonicated in an ice-cold water 
bath for 5 min, and finally centrifuged at 16000 g for 10 min at 4 °C. The organic phase 
was collected and transferred into scintillation tubes. The radioactivity was measured by 
adding 3 mL of Ultima Gold scintillation liquid (PerkinElmer Life Sciences) using a Packard 
Tri-Carb 2100 TR scintillation counter (PerkinElmer Life Sciences). Data were collected 
from at least three independent experiments performed in triplicate, and results were 
expressed as intracellular [3H]AEA reduction in percentage of the vehicle-treated 
samples. 
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